The Tumor Immune Microenvironment and Frameshift Neoantigen Load Determine Response to PD-L1 Blockade in Extensive-Stage SCLC

Hiroaki Kanemura, MD, MPH, a Hidetoshi Hayashi, MD, PhD, a, n Shuta Tomida, PhD, b Junko Tanizaki, MD, PhD, a, c Shinichiro Suzuki, MD, PhD, a, c Yusuke Kawanaka, MD, a, c Asuka Tsuya, MD, d Yasushi Fukuda, MD, e Hiroyasu Kaneda, MD, PhD, f Keita Kudo, MD, g Takayuki Takahama, MD, PhD, h Ryosuke Imai, MD, i Koji Haratani, MD, PhD, j Yasutaka Chiba, PhD, j Tomoyuki Otani, MD, k Akihiko Ito, MD, PhD, k Kazuko Sakai, PhD, l Kazuto Nishio, MD, PhD, l Kazuhiko Nakagawa, MD, PhD a

*Corresponding author.

Disclosure: Dr. Kanemura has received support for the present study from AstraZeneca K.K., Boehringer Ingelheim Japan Inc., Bristol-Myers Squibb Co. Ltd., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Kyorin Pharmaceutical Co. Ltd., Merck Biopharma Co. Ltd., Merck Sharp & Dohme K.K., Novartis Pharmaceuticals K.K., Ono Pharmaceutical Co. Ltd., Taiho Pharmaceutical Co. Ltd., and Takeda Pharmaceutical Co. Ltd.; consulting fees from AstraZeneca K.K., Boehringer Ingelheim Japan Inc., Bristol-Myers Squibb Co. Ltd., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Pfizer Japan Inc., Shanghai Hailie Biopharma, Takeda Pharmaceutical Co. Ltd., and Merck Biopharma Co. Ltd.; and research funding from AstraZeneca K.K., Astellas Pharma Inc., Merck Sharp & Dohme K.K., Ono Pharmaceutical Co. Ltd., Novartis Pharmaceutical K.K., Pfizer Japan Inc., Bristol-Myers Squibb Co. Ltd., Eli Lilly Japan K.K., Chugai Pharmaceutical Co. Ltd., Daiichi-Sankyo Co. Ltd., Merck Serono Co. Ltd., Merck Biopharma Co. Ltd., Takeda Pharmaceutical Co. Ltd., Taiho Pharmaceutical Co. Ltd., Symbio Pharmaceuticals Limited, Abbvie Inc., inVentiv Health Japan, ICON Japan K.K., Gritstone Oncology Inc., Parexel International Corp., Kissei Pharmaceutical Co. Ltd., EPS Corporation, Syneos Health, Pfizer R&D Japan G.K., A2 Healthcare Corp., Quintiles Inc./IQVIA Services Japan K.K., EP-CSRU Co. Ltd., Linical Co. Ltd., Eisai Co. Ltd., CMIC Shift Zero K.K., Kyowa Hakko Kirin Co. Ltd., Bayer Yakuhin Ltd., EPS International Co. Ltd., and Otsuka Pharmaceutical Co. Ltd. Dr. Tomida has received honoraria from Chugai Pharmaceutical Co. Ltd. and Illumina Inc. Dr. Tanizaki has received honoraria from AstraZeneca K.K., Boehringer Ingelheim Japan Inc., Bristol-Myers Squibb Co. Ltd., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Taiho Pharmaceutical Co. Ltd., and Merck Sharp & Dohme K.K. Dr. Fukuda has received lecture fees from AstraZeneca K.K., Daiichi-Sankyo Co. Ltd., Chugai Pharmaceutical Co. Ltd., Merck Biopharma Co. Ltd., Taiho Pharmaceutical Co. Ltd., Bristol-Myers Squibb Co. Ltd., Novartis Boehringer Ingelheim Co. Ltd., and Kyorin Pharmaceutical Co. Ltd. Dr. Kaneda has received honoraria from Chugai Pharmaceutical Co. Ltd. and AstraZeneca K.K. Dr. Takahama has received honoraria from AstraZeneca K.K., Roche Diagnostics, Boehringer Ingelheim Japan Inc., Chugai Pharmaceutical Co. Ltd., and Pfizer Japan Inc. Dr. Haratani has received honoraria from AS ONE Corp., AstraZeneca K.K., Bristol-Myers Squibb Co. Ltd., Chugai Pharmaceutical Co. Ltd., Merck Sharp & Dohme K.K., and Ono Pharmaceutical Co. Ltd. and research funding from AstraZeneca K.K. and Merck Sharp & Dohme K.K. Dr. Chiba has received honoraria from Chugai Pharmaceutical Co. Ltd. Dr. Sakai has received honoraria from Roche Diagnostics, Bio-Rad, AstraZeneca K.K., Chugai Pharmaceutical Co. Ltd., and Hitachi. Dr. Nishio has received honoraria from Boehringer Ingelheim Japan Inc., Chugai Pharmaceutical Co. Ltd., Eisai Co. Ltd., Pfizer Japan Inc., Novartis Pharmaceuticals K.K., Merck Sharp & Dohme K.K., Ono Pharmaceutical Co. Ltd., Bristol-Myers Squibb Co. Ltd., Life Technologies Japan, Yakult Honsha, Roche Diagnostics, AstraZeneca K.K., Sanofi, Guardant Health, Amgen, and Merck Biopharma Co. Ltd.; consulting fees from Solasia Pharma, Otsuka Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Bayer Yakuhin Ltd., Eli Lilly Japan K.K., Merck Biopharma Co. Ltd., Novartis Pharmaceuticals K.K., and SymBio Pharmaceuticals; and research funding from Ignyta Inc., Eli Lilly Japan K.K., Nippon Boehringer Ingelheim Co. Ltd., Korea Otsuka Pharmaceutical Co. Ltd., and Nichirei Biosciences Inc. Dr. Nakagawa has received honoraria from AstraZeneca K.K., Chugai Pharmaceutical Co. Ltd., Nippon Kayaku Co. Ltd., Takeda Pharmaceutical Co. Ltd., Ono Pharmaceutical Co. Ltd., Roche Diagnostics K.K., Astellas Pharma Inc., Merck Sharp & Dohme K.K., Bayer Yakuhin Ltd., Eli Lilly Japan K.K., Merck Biopharma Co. Ltd., Kyorin Pharmaceutical Co. Ltd., Thermo Fisher Scientific K.K., Hisamitsu Pharmaceutical Co. Inc., Nanzo Co. Ltd., Daiichi-Sankyo Co. Ltd., Novartis Pharma K.K., Kyowa Kirin Co. Ltd., Medical Mobile Communications Co. Ltd., Yomiuri Telecasting Corp., Nikkei Business Publications Inc., Nippon Boehringer Ingelheim Co. Ltd., Medicus Shuppan Publishers Co. Ltd., Taiho Pharmaceutical Co. Ltd., Pfizer Japan Inc., Abbvie Inc., Bristol-Myers Squibb Co. Ltd., Carenet Inc., AstraZeneca K.K., Taiho Pharmaceutical Co. Ltd., Pfizer Japan Inc., Ono Pharmaceutical Co. Ltd., and Kyorin Pharmaceutical Co. Ltd.; and research funding from Takeda Pharmaceutical Co. Ltd., Taiho Pharmaceutical Co. Ltd., Abbvie Inc., GlaxoSmithKline K.K., Parexel International Corp., ICON Japan K.K., EPS Corporation, Syneos Health, IQVIA Services Japan K.K., A2 Healthcare Corp., CMIC Shift Zero K.K., Eisai Co. Ltd., SymBio Pharmaceuticals Limited, Kyowa Kirin Co. Ltd., Bayer Yakuhin Ltd., EPS International Co. Ltd., Otsuka Pharmaceutical Co. Ltd., PRA Health Sciences, Covance Japan Inc., Medical Research Support, Sanofi K.K., PPD-SNBL K.K., Japan Clinical Research Operations, Sysmex Corp., and Mochida Pharmaceutical Co. Ltd. The remaining authors declare no conflict of interest.

Address for correspondence: Hidetoshi Hayashi, MD, PhD, Department of Medical Oncology, Kindai University Faculty of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, Osaka 589-8511, Japan. E-mail: hidet31@med.kindai.ac.jp

Cite this article as: Kanemura H, Hayashi H, Tomida S, et al. The tumor immune microenvironment and frameshift neoantigen load determine response to programmed death-ligand 1 blockade in extensive-stage SCLC. JTO Clin Res Rep. 2022;3:100373.

© 2022 The Authors. Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

ISSN: 2666-3643

https://doi.org/10.1016/j.jtocrr.2022.100373
ABSTRACT

Introduction: Despite a considerable benefit of adding immune checkpoint inhibitors (ICIs) to platinum-based chemotherapy for patients with extensive-stage SCLC (ES-SCLC), a durable response to ICIs occurs in only a small minority of such patients.

Methods: A total of 135 patients with ES-SCLC treated with chemotherapy either alone (chemo-cohort, n = 71) or together with an ICI (ICI combo-cohort, n = 64) was included in this retrospective study. Tumors were classified pathologically as inflamed or noninflamed on the basis of programmed death-ligand 1 expression and CD8+ tumor-infiltrating lymphocyte density. Immune-related gene expression profiling was performed, and predicted neoantigen load was determined by whole-exome sequencing.

Results: Among patients in the ICI combo-cohort, median progression-free survival was 10.8 and 5.1 months for those with inflamed (n = 7) or noninflamed (n = 56) tumors, respectively (log-rank test p = 0.002; hazard ratio of 0.26). Among the 89 patients with immune-related gene expression profiling data available, inflamed tumors had a higher T cell-inflamed GEP score than did noninflamed tumors (−0.18 versus −0.58, p < 0.001). The 12-month progression-free survival rate was 16.1% and 0% for patients in the ICI combo-cohort harboring tumors with a high (n = 26) or low (n = 18) frameshift neoantigen load, respectively. A high-frameshift neoantigen load was associated with up-regulation of gene signatures related to antigen presentation and costimulatory signaling. A durable clinical benefit of ICI therapy was observed only in patients with inflamed tumors and a high-frameshift neoantigen load.

Conclusions: Expression of programmed death-ligand 1, CD8+ T cell infiltration, and a high-frameshift neoantigen load are associated with clinical benefit of ICI therapy in ES-SCLC.

Clinical trial registration: UMIN000041056

Keywords: Small cell lung cancer; Immunotherapy; Tumor-infiltrating lymphocyte; Tumor mutation burden; Neoantigen

Introduction

SCLC is an aggressive high-grade neuroendocrine tumor with a low survival rate. It accounts for approximately 15% of lung cancer cases worldwide and is the sixth leading cause of cancer-related death. The standard treatment for SCLC remained unchanged for several decades, with no improvement in survival time. Recently, however, phase 3 trials have revealed a substantial survival advantage for the addition of antibodies to programmed death-ligand 1 (PD-L1) to first-line chemotherapy for extensive-stage SCLC (ES-SCLC), although the benefit of this new treatment strategy is restricted to a small subset of patients, in part because of a limited understanding of both the disease and the key determinants of a response to immunotherapy.

SCLC is strongly associated with smoking and therefore has a relatively high tumor mutation burden (TMB), suggesting that it might be responsive to immune checkpoint inhibitors (ICIs). Nevertheless, only approximately 20% of SCLC tumors have a tumor proportion score for PD-L1 of more than or equal to 1%. A better understanding of the transcriptomic and genomic features of SCLC is therefore needed to inform the development of optimal therapeutic strategies.

We hypothesized that a comprehensive molecular analysis of the tumor immune microenvironment (TME) and genomic underpinnings of tumor antigenicity for SCLC might reveal immunologic determinants of the response or resistance to immunotherapy and thereby support both the identification of patients likely to derive the most benefit from such treatment and the
development of new therapeutic approaches. We have therefore now performed an exploratory study to characterize the pathologic, transcriptomic, and genetic immune profiles of SCLC.

Materials and Methods

Patients
We reviewed the medical records of all individuals with pathologically confirmed ES-SCLC treated at the study hospitals between January 2015 and January 2021. Patients diagnosed on the basis of cytology only or with insufficient residual tissue specimens were excluded from biomarker analysis. The chemo-cohort comprised patients treated with platinum-based chemotherapy without an ICI, whereas the ICI combo-cohort comprised those treated with such chemotherapy in combination with an ICI. Among individuals who received prior chemoradiotherapy for limited-stage SCLC, those who had been treated with curative intent and experienced a treatment-free interval of at least 6 months after the last chemoradiotherapy, radiotherapy, or chemoradiotherapy cycle and before the diagnosis of ES-SCLC were also included. The study was conducted according to the Declaration of Helsinki and protocols approved by the institutional review board of each participating hospital. (Kindai University Hospital, Kishiwada City Hospital, Izumi City General Hospital, Kurashiki Central Hospital, Osaka City University Hospital, National Hospital Organization Osaka Minami Medical Center, Kindai University Nara Hospital, St. Luke’s International Hospital). All patients provided written informed consent, where applicable, or such informed consent was waived by institutional review board–approved protocols for aggregate deidentified data analysis.

Data Collection

Medical records were reviewed, and data regarding clinicopathologic features and treatment history were extracted. The data cutoff date was June 30, 2021. Tumor response was assessed by computed tomography every 6 to 8 weeks according to the Response Evaluation Criteria in Solid Tumors, version 1.1. Progression-free survival (PFS) was measured from treatment initiation to clinical or radiographic progression or death from any cause. Patients without documented clinical or radiographic disease progression were censored on the date of last follow-up.

Statistical Analysis

Categorical and continuous variables were summarized descriptively as percentage and median values. Differences in continuous variables were assessed with the Wilcoxon ranked sum test and those in categorical variables with Fisher’s exact test. Comparisons among more than two groups were performed with Dunn’s test. Correlations were evaluated with the Spearman correlation test. The Benjamini-Hochberg method was applied to calculate the false discovery rate (FDR) for multiple testing. Differences in PFS curves constructed by the Kaplan-Meier method were assessed with the log-rank test, and the Cox proportional hazard regression model was adopted to determine hazard ratios (HRs). All p values are two-sided and confidence intervals (CIs) are at the 95% level, with statistical significance defined as a p value of less than 0.05 (with the exception of Dunn’s test, p < 0.025). Statistical analysis was performed with Stata IC version 14.2 (StataCorp LP) or GraphPad Prism 7.0 (GraphPad Software).

Assessment of Pathologic, Transcriptomic, and Genetic Immune Profiles

Protocols for immunohistochemistry, assessment of immune-related gene expression, and whole-exome sequencing (WES) are described in the Supplementary Methods.

Results

Patient Characteristics

A total of 135 patients who were treated between January 2015 and January 2021 and who had baseline tissue specimens available was enrolled, with 71 patients in the chemo-cohort and 64 patients in the ICI combo-cohort. Patient flow is summarized in Supplementary Figure 1. Demographic characteristics were well balanced between the two cohorts (Table 1).

TME Classification on the Basis of PD-L1 Expression and CD8+ TIL Density

Median follow-up time was 32.9 months (range: 0.6–37.8 mo) for the chemo-cohort and 15.9 months (range: 1.8–20.8 mo) for the ICI combo-cohort. Median PFS was 4.8 months (95% CI: 4.2–5.3 mo) and 5.3 months (95% CI: 4.6–5.7 mo) in the chemo-cohort and ICI combo-cohort, respectively. The 12-month PFS rate was 4.4% (95% CI: 1.1%–11.1%) and 11.1% (95% CI: 4.9%–20.2%) in the chemo-cohort and ICI combo-cohort, respectively (Supplementary Fig. 2A and B).

The 133 patients for whom both PD-L1 and CD8 expression data were available were stratified into four TME groups on the basis of cutoffs of 1% for PD-L1 combined positive score (CPS) and of the median (85/ mm²) for CD8+ tumor-infiltrating lymphocyte (TIL) density (Fig. 1A). We defined PD-L1positive (CPS of ≥1%) and CD8+ TILhigh (>85/mm²) tumors on the basis of this stratification as “inflamed tumors” and all other tumors as “noninflamed tumors.” For the ICI combo-cohort (n =
63), median PFS was 10.8 months (95% CI: 3.5 mo–not reached; n = 7) in patients with inflamed tumors versus 5.1 months (95% CI: 4.3–5.6 mo; n = 56) in those with noninflamed tumors (log-rank test p = 0.002, HR = 0.26, 95% CI: 0.09–0.74), with 12-month PFS rates of 42.9% (95% CI: 9.8%–73.4%) and 5.5% (95% CI: 1.4%–13.7%), respectively (Fig. 1B). In contrast, for the chemo-cohort (n = 70), there was no significant difference in PFS between inflamed and noninflamed tumors (median of 3.6 mo [95% CI: 3.1–5.5 mo] versus 4.8 months [95% CI: 4.4–5.7 mo], respectively; log-rank test p = 0.11; HR = 1.70, 95% CI: 0.92–3.14), with 12-month PFS rates of 0% and 5.5% (95% CI: 1.5%–13.8%), respectively (Fig. 1C). These results suggested that the combination of PD-L1 CPS and CD8+ TIL density might serve as a potential biomarker for patient selection with regard to immunotherapy in SCLC.

**Transcriptomic Features of the TME According to PD-L1 Expression and CD8+ TIL Density**

We next performed immune-related gene expression profiling (irGEP) for 50 and 39 tumor samples obtained from the chemo-cohort and ICI combo-cohort, respectively, to evaluate the immune profile of SCLC in more detail. A T cell–inflamed GEP score was calculated as a weighted sum of normalized expression values for 18 genes, as described previously, with this score having been found to be associated with benefit of immunotherapy in solid tumors. Among the 89 studied patients, the 17 individuals with inflamed tumors had a higher T cell–inflamed GEP score than did the 72 individuals with noninflamed tumors (−0.18 versus −0.58, p < 0.001) (Fig. 2A).

We further investigated the immunologic characteristics of inflamed tumors (n = 17) and noninflamed

| Characteristics | Chemo-Cohort (n = 71) | ICI Combo-Cohort (n = 64) | p Valueb |
|----------------|-----------------------|---------------------------|----------|
| Median age (range), yc | 73 (35–84) | 72 (34–83) | 0.384 |
| Sex | | | |
| Male | 55 (77.5) | 53 (82.8) | 0.520 |
| Female | 16 (22.5) | 11 (17.2) | |
| ECOG performance status0-1 | 54 (76.1) | 55 (85.9) | 0.293 |
| 2 | 12 (16.9) | 5 (7.8) | |
| 3-4 | 5 (7.0) | 4 (6.3) | |
| Smoking statusd | | | |
| Current or former | 68 (95.8) | 63 (98.4) | 0.687 |
| Never | 2 (2.8) | 1 (1.6) | |
| Unknown | 1 (1.4) | 0 (0) | |
| Stage | | | |
| Limited | 8 (11.3) | 4 (6.3) | 0.374 |
| Extensive | 63 (88.7) | 60 (93.8) | |
| Metastasis at baseline | | | |
| CNS | 17 (23.9) | 20 (31.2) | 0.440 |
| Intrathoracic only | 9 (12.7) | 9 (14.1) | 1.00 |
| Extrathoracic | 54 (76.1) | 52 (81.3) | 0.532 |
| Histologic diagnosis | | | |
| Small cell | 66 (93.0) | 61 (95.3) | 0.721 |
| Combined | 5 (7.0) | 3 (4.7) | |
| Treatment | | | |
| Surgery | 9 (12.7) | 4 (6.3) | 0.252 |
| Radiotherapy | 4 (5.6) | 6 (9.4) | 0.517 |
| PD-L1 TPS (22C3) | | | |
| ≥1% | 3 (4.2) | 3 (4.7) | 1.00 |
| <1% | 68 (95.8) | 61 (95.3) | |
| PD-L1 CPS (22C3) | | | |
| ≥1% | 18 (25.4) | 9 (14.1) | 0.132 |
| <1% | 53 (74.6) | 55 (85.9) | |

**Table 1. Characteristics of the Study Patients**

*aPercentages may not add up to 100 because of rounding.
bp Values were determined with the Wilcoxon rank sum test or Fisher’s exact test as appropriate.
cAt the start of treatment.
dCurrent smokers, individuals who had smoked a cigarette within the previous year; former smokers, those who had smoked more than or equal to 100 cigarettes but had quit more than 1 year before diagnosis; never smokers, those who had smoked less than 100 cigarettes.

CNS, central nervous system; CPS, combined positive score; ECOG, Eastern Cooperative Oncology Group; ICI, immune checkpoint inhibitor; PD-L1, programmed death-ligand 1; TPS, tumor proportion score.
tumors (n = 72). We thus performed unsupervised analysis of 676 immune-related genes for the 89 samples subjected to irGEP (Fig. 2B). On the basis of the hierarchical clustering for the 89 patients illustrated in Figure 2B, we selected two gene clusters that were expressed at a higher level in inflamed tumors (cluster 1, 217 genes) or in noninflamed tumors (cluster 2, 169 genes). Cluster 1 (n = 217 genes) contained genes related to costimulatory T cell signaling (n = 26 genes, including CD48, CD80, CD274, IL18, IL18BP, PTPRC, IL2RA, and IL15), cytokine and chemokine signaling (n = 25 genes, including CXCL10, IL2RA, IL10RA, and JAK3), and antigen presentation (n = 34 genes, including CTSS and HLA-DRA, -DMA, -DMB, -DOA, -DPA1, and -DPB1). In contrast, cluster 2 (n = 169 genes) contained genes related to cell proliferation (n = 28 genes, including ANLN, BIRC5, CCNE1, CENPF, MKI67, MELK, RRM2, TYMS, TP53, and UBE2C) and DNA damage repair (n = 20 genes, including BRCA1, BRCA2, BRIP1, EXO1, MSH2, MSH6, and UBE2C).

We also evaluated differential expression of individual genes with the 89 tumor specimens to shed light on differentially enriched processes in inflamed tumors versus noninflamed tumors. Genes related to cytotoxic lymphocytes (such as GZMA), costimulatory molecules (such as CD274 and TIGIT), and cytokine and chemokine signaling (such as IL2RG, IL2RA, CXCL9, and CXCL10) were among those expressed at a significantly higher level in inflamed tumors (Fig. 2C and Supplementary Fig. 3A). In contrast, SOX11 (p < 0.001, FDR < 0.001) and MYC (p = 0.02, FDR = 0.06) were the top two up-regulated genes in noninflamed tumors relative to inflamed tumors, suggesting SOX11 and MYC might contribute to poor immunoreactivity in SCLC (Fig. 2C and Supplementary Fig. 3A). We further investigated whether MYC might be a determinant of ICI efficacy. Patients in each cohort were divided into two groups according to the median value for MYC expression (Supplementary Fig. 4A and B). For the ICI combo-cohort (n = 39), median PFS was 4.0 months (95% CI: 3.1–5.4 mo; n = 22) in patients with MYChigh tumors versus 5.3 months (95% CI: 4.6–7.3 mo; n = 17) in those with MYC low tumors (log-rank test p = 0.028, HR = 2.18, 95% CI: 1.08–4.40), with 12-month PFS rates of 4.6% (95% CI: 0.3%–18.9%) and 23.5% (95% CI: 7.3%–44.9%), respectively. In contrast, for the chemo-cohort (n = 50), there was no significant difference in PFS between MYChigh and MYC low tumors (median of 4.8 mo [95% CI: 3.6–5.5 mo; n = 23] versus 4.9 mo [95% CI: 4.3–5.9 mo; n = 27], respectively; log-rank test p = 0.77, HR = 1.09, 95% CI: 0.61–1.94). These results thus indicated that MYC expression was negatively associated with ICI progression.
eas were performed to evaluate any difference in PFS rates between these two groups in either cohort, likely due in part to the small sample size (data not shown). We also performed an analysis to evaluate any difference in treatment outcome according to the median value of TIGIT expression. There was no significant difference in PFS between TIGIT\textsuperscript{high} and TIGIT\textsuperscript{low} groups of either the ICI combo-cohort or the chemo-cohort (data not shown).

Among the up-regulated genes in inflamed tumors, TIGIT encodes a member of the immunoglobulin superfamily of proteins that is expressed on the surface of T cells and natural killer cells and which has recently been evaluated as a potentially targetable immune checkpoint molecule.\textsuperscript{20} We found that the expression level of TIGIT was moderately correlated with TIGIT\textsuperscript{+} TIL density as determined by immunohistochemistry (Spearman correlation coefficient \( r = 0.32, p = 0.006 \)) (Supplementary Fig. 3B) and that TIGIT\textsuperscript{+} TIL density was significantly higher in inflamed tumors than in noninflamed tumors (75/mm\textsuperscript{2} [95% CI: 25–144/mm\textsuperscript{2}] versus 25/mm\textsuperscript{2} [95% CI: 25–25/mm\textsuperscript{2}], \( p = 0.002 \)) (Fig. 2D and Supplementary Fig. 3C). These findings thus implicated TIGIT as a potentially targetable molecule in inflamed tumors.

Moreover, our data revealed that the expression of gene signatures related to cell proliferation or to DNA damage repair was significantly higher in noninflamed tumors than in inflamed tumors (\( p < 0.001 \) and \( p < 0.001 \), respectively) (Fig. 2E). The expression of these gene signatures was inversely correlated with that of other immune-related pathway signatures in the 89 tumor specimens analyzed (Supplementary Fig. 3D).

Collectively, our irGEP analysis suggested that a T cell-inflamed gene expression profile might play an important role in promoting anticancer immunity, with the increased expression of genes related to
costimulatory signaling, cytokine and chemokine signaling, and antigen presentation providing a potential explanation for the more favorable response of inflamed tumors to ICIs. Conversely, up-regulation of gene signatures related to cell proliferation and DNA damage repair might contribute to the acquisition of an immunosuppressive phenotype. The mechanisms by which cell proliferation and DNA damage repair might contribute to the acquisition of an immunosuppressive phenotype require further investigation.

**Genomic Features of Tumor Antigenicity in SCLC**

TMB is an indirect measure of tumor antigenicity and might play a role in the recognition of cancer cells by the immune system.\(^{21,22}\) Tumor neoantigens are mutant peptides generated as a result of genetic mutations and are capable of eliciting an antitumor T cell response.\(^{23,24}\) Although SCLC has a high TMB and would therefore be expected to induce a strong T cell response, the response to ICIs is limited to less than 15% of patients with SCLC.\(^{25,26}\) Neoantigens generated by insertion-deletion (indel) mutations have been found to be enriched relative to those generated by nonsynonymous single-nucleotide variants (nsSNVs) in various cancer types.\(^{21}\)

Furthermore, a high load of frameshift neoantigens was associated with increased expression of genes related to immune activation, whereas a high load of nsSNV neoantigens was not.\(^{21}\) On the basis of these findings, we defined TMB broadly in our study as the total number of SNVs (synonymous and nonsynonymous) and indels per tumor genomic region analyzed. In addition, our bioinformatics pipelines for the prediction of neoantigens focused on those derived from nsSNVs and frameshift indels (fs-indels).

We first compared the distribution of TMB between SCLC and lung adenocarcinoma (LUAD), with WES data for 20 patients with LUAD (top 10 and bottom 10 TMB samples) being obtained from The Cancer Genome Atlas (TCGA). As expected, the SCLC tumors in our cohort (n = 85) had a higher TMB compared with LUAD tumors with the top 10 highest TMB values from TCGA (median TMB of 6.8/megabase [Mb] [95% CI: 6.0–7.6/Mb] versus 2.9/Mb [95% CI: 2.1–5.3/Mb], p < 0.001) (Fig. 3A).
We next evaluated the relation of TMB to PFS in the ICI combo-cohort of our patients with SCLC (n = 44). PFS did not differ significantly between patients with a high versus low TMB (median of 5.1 mo [95% CI: 3.9–6.5 mo] versus 5.6 mo [95% CI: 4.3–6.3 mo], respectively; log-rank test \( p = 0.93 \); HR = 0.97, with a 95% CI: 0.52–1.83), with 12-month PFS rates of 12.5% (95% CI: 3.1%–28.7%) and 5.3% (95% CI: 0%–21.5%), respectively (Fig. 3B). Similarly, in the chemo-cohort (n = 41), the median PFS was 5.3 months (95% CI: 3.8–6.4 mo) for the high-TMB group and 4.4 months (95% CI: 3.2–5.1 mo) for the low-TMB group (log-rank test \( p = 0.18 \); HR = 0.64, with a 95% CI: 0.34–1.23), with corresponding 12-month PFS rates of 11.8% (95% CI: 0.4%–21.9%) and 0% (Supplementary Fig. 5A). These findings suggested that a high TMB was not associated with a clinical benefit of ICI treatment.

We next investigated the potential immunogenicity of nsSNVs and fs-indels in SCLC by prediction of major histocompatibility complex class I–associated neoantigens (Table 2). Analysis of the total of 21,059 nsSNVs detected in the 85 SCLC tumors predicted 3299 high-affinity neoantigens (defined as epitopes with a predicted binding affinity of <50 nM), corresponding to a rate of 0.16 neoantigens per nsSNV. Similar analysis for the total of 1346 fs-indels predicted 662 high-affinity binders, corresponding to a rate of 0.49 neoantigens per fs-indel. Frameshift mutations were thus predicted to generate three times as many neoantigens per mutation as were SNVs, consistent with recent findings for various cancer types.21 We performed the same analysis for the TCGA-LUAD data set and found that fs-indels were predicted to give rise to five or 30 times as many neoantigens as were nsSNVs for the top 10 and bottom 10 tumors ranked according to TMB, respectively (Table 2). We then defined the proportion of fs-indels for each tumor as the number of fs-indels divided by the total number of indels and SNVs. The median number of fs-indels tended to be lower in SCLC than in the top 10 LUAD tumors ranked by TMB (13 [95% CI: 10–15] versus 20 [95% CI: 13–34], \( p = 0.03 \)) (Fig. 3C), and the proportion of fs-indels in SCLC was significantly lower than in these 10 LUAD tumors (0.018 [95% CI: 0.015–0.021] versus 0.86 [95% CI: 0.41–1.37], \( p < 0.001 \)) (Fig. 3D). These findings suggested that the lower number and proportion of fs-indels, and consequent lower load of frameshift neoantigens, might contribute to the limited efficacy of ICIs in SCLC compared with LUAD.

We next calculated PFS according to predicted frameshift neoantigen load in the ICI combo-cohort of our patients with SCLC (n = 44). The patients were thus split into two groups on the basis of the median number of frameshift neoantigens. The median PFS was 5.7 months (95% CI: 4.1–6.8 mo) for the high-frameshift neoantigen group and 5.1 months (95% CI: 4.3–5.6 mo) for the low-frameshift neoantigen group (log-rank test \( p = 0.12 \); HR = 0.60, with a 95% CI: 0.31–1.14), with corresponding 12-month PFS rates of 16.1% (95% CI: 5.1%–32.7%) and 0% (Supplementary Fig. 5A). These findings suggested that a high TMB was not associated with a clinical benefit of ICI treatment.

### Table 2. Predicted Neoantigens for SCLC (This Study) and LUAD (TCGA)

| Tumor Type       | Mutations (n) | Neoantigens (n) | Neoantigens Per Mutation |
|------------------|---------------|-----------------|--------------------------|
| SCLC (n = 85)    |               |                 |                          |
| nsSNVs           | 21,059        | 3299            | 0.16                     |
| fs-indels        | 1346          | 662             | 0.49                     |
| fs-indel enrichment |            |                 | 3.14                     |
| LUAD (top 10 for TMB) |            |                 |                          |
| nsSNVs           | 1013          | 118             | 0.12                     |
| fs-indels        | 219           | 132             | 0.60                     |
| fs-indel enrichment |            |                 | 5.17                     |
| LUAD (bottom 10 for TMB) |           |                 |                          |
| nsSNVs           | 38            | 3               | 0.08                     |
| fs-indels        | 20            | 47              | 2.35                     |
| fs-indel enrichment |            |                 | 29.8                     |

LUAD, lung adenocarcinoma; TCGA, The Cancer Genome Atlas; nsSNVs, nonsynonymous single-nucleotide variants; fs-indels, frameshift insertions and deletions; TMB tumor mutation burden.

Association of Immune Signatures Related to Antigen Presentation or Costimulatory Signaling With Frameshift Neoantigens

To explore further the different effects of TMB and frameshift neoantigen load on immune responses, we
evaluated the relation between these two parameters and immune-related gene expression. Patients with SCLC were split into groups on the basis of the median values of TMB (high defined as $\geq 6.85/\text{Mb}$) and frameshift neoantigen load (high defined as $\geq 5$ frameshift neoantigens per case). A high load of frameshift neoantigens was associated with a high expression level for immune signatures related to antigen presentation and to costimulatory signaling, whereas a high TMB was associated with a high expression level for immune signatures related to cell proliferation and DNA damage repair (Fig. 4A). These findings were similar to the differences in gene expression signatures between inflamed and noninflamed tumors (Fig. 2B–E), consistent with the notion that frameshift neoantigen load is associated with ICI efficacy in SCLC.

We next evaluated the relation between frameshift neoantigen load and the T cell–inflamed GEP score, which we found was higher in inflamed tumors than in noninflamed tumors (Fig. 2A). There was no correlation between these measures (Fig. 4B), suggesting the effect of frameshift neoantigen load on ICI efficacy was independent of the T cell–inflamed GEP score.

Finally, we evaluated the clinical utility of the combination of inflammation category (inflamed or noninflamed) and frameshift neoantigen load. Among the 64 patients in the ICI combo-cohort, the 24 individuals with available data were stratified into four groups on the basis of inflammation category and the median frameshift neoantigen load (high defined as $\geq 5$ frameshift neoantigens per case). A durable clinical benefit (PFS of $\geq 12$ mo) was apparent only in patients with both inflamed tumors and a high-frameshift neoantigen load (Fig. 4C). Collectively, these results suggested that the expression of PD-L1 and CD8$^+$ T cell infiltration, together with a high-frameshift neoantigen load associated with the up-regulation of gene expression signatures related to antigen presentation and costimulatory signaling, might confer a durable clinical benefit of ICI therapy in SCLC.

![Figure 4. Classification of SCLC tumors on the basis of PD-L1 expression, CD8$^+$ tumor-infiltrating lymphocyte density, immune-related gene expression, and neoantigen status. (A) Change of median gene signature expression in high versus low groups of SCLC tumors ($n = 55$) classified according to the median values for the predicted number of frameshift neoantigens or tumor mutation burden. The change of median gene signature expression is represented by the color scale, with the highest values illustrated in red, median in white, and lowest in blue. (B) Relation of the predicted number of frameshift neoantigens to the T cell–inflamed GEP score for SCLC tumors ($n = 55$). The $p$ value was determined with the Spearman correlation test. (C) Kaplan-Meier curves of progression-free survival for the ICI combo-cohort of patients with SCLC classified according to inflamed versus noninflamed status and predicted frameshift neoantigen load (high defined as $\geq 5$ frameshift neoantigens per case). CI, confidence interval; GEP, gene expression profiling; ICI, immune checkpoint inhibitor; NR, not reached.](image-url)
Discussion

Our results have revealed that PD-L1 expression and CD8+ TIL density together are able to predict which patients with ES-SCLC are likely to derive clinical benefit from the combination of platinum-based chemotherapy and ICI therapy. In addition, a high-frameshift neoantigen load tended to be more associated with clinical benefit from ICI treatment than was a high TMB. Our irGEP analysis implicated a T cell–inflamed TME primed for a response to immunotherapy and up-regulation of gene expression related to costimulatory signaling, cytokine and chemokine signaling, and antigen presentation as determinants of the antitumor immune response.

Although classification of tumors into groups on the basis of PD-L1 status and the presence of TILs has been proposed for other cancer types, SCLC has not previously been evaluated for the relation between immune characteristics and clinical outcome of chemoinmunotherapy. Not unexpectedly, we found that pathologically inflamed SCLC tumors as defined on the basis of PD-L1 expression level and CD8+ TIL density received a greater benefit from anticancer immunotherapy. We also identified additional distinct transcriptomic features of these tumors including the up-regulation of gene expression related to costimulatory signaling, cytokine and chemokine signaling, and antigen presentation.

Consistent with the finding that 12.6% of patients with ES-SCLC received a durable clinical benefit (PFS of ≥12 mo) from chemotherapy plus an ICI in the IMpower133 trial, 11.1% of the patients with ES-SCLC in our cohort had such a benefit. In our cohort, 85% of patients were classified as having noninflamed tumors. Although a phase 3 trial revealed no benefit from adding an antibody to CTLA-4 and an anti–PD-L1 antibody to platinum-based chemotherapy for patients with ES-SCLC, our results suggest that the approximately 85% of patients with noninflamed tumors might be amenable to combination therapy designed to promote T cell infiltration. Nevertheless, of our patients with ES-SCLC, 15% were classified as having inflamed tumors, but, among the seven of these patients in the ICI combo-cohort, only three had a durable clinical benefit (PFS of ≥12 mo). Moreover, given that TIGIT+ TIL density was significantly higher in inflamed tumors than in noninflamed tumors (p = 0.002), the combination of an agent that targets TIGIT with a currently available ICI might be a promising treatment approach. A large phase 3 trial (NCT04256421, SKYSCRAPER-02) of the TIGIT inhibitor tiragolumab in combination with atezolizumab-carboplatin-etoposide for ES-SCLC is currently ongoing.

Our exploratory irGEP analysis provided insight into the mechanisms underlying the limited efficacy of ICIs for SCLC, with gene expression signatures related to DNA damage repair and cell proliferation and the expression of SOX11 and MYC being implicated in the lack of immunogenicity. Previous studies have found that genes related to DNA damage repair are expressed at a higher level in SCLC than in LUAD and that SCLC becomes dependent on such repair pathways for tumor maintenance. SOX11 is a neuronal differentiation factor and promotes neuroendocrine differentiation of cancer. Neuroendocrine-high SCLC was recently found to be associated with reduced levels of immune cell infiltration and expression of immune checkpoint–related molecules including PVR, IDO, major histocompatibility complex class II, and TIM3 compared with neuroendocrine-low SCLC. SOX11 might therefore contribute to immunosuppression by inducing neuroendocrine differentiation in SCLC. The MYC protooncogene encodes a transcription factor that is overexpressed in many human cancer types, and dysregulation of MYC signaling is implicated in the molecular and histologic heterogeneity of SCLC. Although MYC activation may influence the antitumor immune response through regulation of CD47 and PD-L1, it’s role in the responsiveness of SCLC to ICI therapy remains under investigation.

TMB has emerged as a potential biomarker for the efficacy of programmed cell death protein 1 inhibitors in several tumor types. Nevertheless, TMB was not predictive of improvement in overall survival by chemoinmunotherapy in ES-SCLC, and we found that a high TMB was not associated with clinical benefit from ICI treatment in our cohort. Instead, we found that TPS in the ICI combo-cohort tended to be more favorable for patients whose tumors had a high-frameshift neoantigen load, although the number of patients in this analysis was relatively small. We also found that a high-frameshift neoantigen load was associated with up-regulation of gene expression related to antigen presentation and costimulatory signaling, whereas a high TMB was associated with that of gene expression related to cell proliferation and DNA damage repair. As far as we are aware, our study is the first to have analyzed neoantigen load in SCLC and to suggest the importance of frameshift neoantigens instead of TMB as a determinant of ICI efficacy. The benefit of ICIs for SCLC is limited compared with that apparent for other solid tumor types, despite the high TMB of SCLC attributable to its association with tobacco exposure. Our neoantigen prediction analysis now suggests that the low number and proportion of fs-indelets in SCLC compared with LUAD might account for the limited efficacy of ICIs.

Although a strength of our study is the inclusion of two different treatment cohorts, the chemo-cohort and the ICI combo-cohort, our study also has several
limitations. First, the study was retrospective in nature and the number of patients was relatively small, precluding multivariate analysis and analysis of a validation cohort. Nevertheless, with the exception of histologic diagnosis in the ICI combo-cohort and central nervous system metastasis in the chemo-cohort, patient characteristics—including performance status, age, and circulating albumin and lactate dehydrogenase levels—were well balanced between individuals with inflamed or noninflamed tumors in the ICI-combo cohort (Supplementary Table 1) and the chemo-cohort (Supplementary Table 2). Second, our molecular data were derived from conventional bulk analysis, involving the processing of a mixture of cell types, and the study was thus not able to assess tumor heterogeneity. Third, we could not evaluate the relation between clinical outcome and the four SCLC subtypes defined by differential expression of the transcription factors ASCL1, NEUROD1, and POU2F3 or low expression of all three transcription factors (SCLC-A, -N, -P, and -I, respectively).41,42 Retrospective analysis of the IMpower133 trial found that the SCLC-inflamed (SCLC-I) subtype responded best to ICI therapy.42 SCLC-I tumors manifest high PD-L1 expression and inflammatory features including high expression of HLA genes and genes related to interferon activation and immune checkpoints,42 and they are therefore similar to the inflamed tumors in our study. We found that 15% of patients with SCLC had inflamed tumors, similar to the frequency of 18% for SCLC-I tumors in IMpower133.

In conclusion, the classification of ES-SCLC tumors into inflamed and noninflamed subtypes on the basis of PD-L1 expression and CD8+ TIL density is a simple approach supported by gene expression analysis to the identification of patients likely to benefit most from the addition of an ICI to chemotherapy. In addition to expression of PD-L1 and CD8+ T cell infiltration, a high-frameshift neoantigen load was associated with a durable clinical benefit from ICI therapy in ES-SCLC. Our study thus provides insight into the pathologic, transcriptomic, and genetic immune profiles of SCLC. Further investigation of inflamed and noninflamed tumors should inform personalized treatment strategies and identify treatment resistance mechanisms in SCLC.

CRediT Authorship Contribution Statement

Hiroaki Kanemura: Conceptualization, data curation, formal analysis, funding acquisition, investigation, writing-original draft, writing-review and editing.

Hidetoshi Hayashi: Conceptualization, funding acquisition, supervision, investigation, project administration, writing-original draft, writing-review and editing.

Shuta Tomida: Formal analysis, investigation, methodology, software, writing-review and editing.

Junko Tanizaki, Yusuke Kawanaka, Asuka Tsuya, Yasushi Fukuda, Hiroyasu Kaneda, Keita Kudo, Takayuki Takahama, Ryosuke Imai: Data curation, resources.

Shinichiro Suzuki: Data curation, methodology, resources.

Koji Haratani, Akihiko Ito, Kazuko Sakai, Kazuto Nishio: Methodology.

Yasutaka Chiba: Formal analysis.

Tomoyuki Otani: Methodology, investigation.

Kazuhiko Nakagawa: Conceptualization, funding acquisition, project administration, supervision, writing-review and editing.

Acknowledgments

The biomarker measurement in this study was funded by Chugai Pharmaceutical Co. Ltd. Chugai Pharmaceutical Co. Ltd. was involved with review and approval of the conflict of interest disclosure and intellectual property but not with the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation of the manuscript; and the decision to submit the manuscript for publication. The authors thank all the patients and medical staff at the participating institutions who contributed to this study; Atsushi Doi (Cell Innovator Inc., Fukuoka, Japan) for technical assistance with WES analysis; and Mami Kitano, Haruka Sakamoto, Michiko Kitano, and Yume Shinkai (Department of Medical Oncology, Kindai University Faculty of Medicine) for technical support.

Supplementary Data

Note: To access the supplementary material accompanying this article, visit the online version of the JTO Clinical and Research Reports at www.jtocrr.org and at https://doi.org/10.1016/j.jtocrr.2022.100373.

References

1. Rudin CM, Brambilla E, Faiivre-Finn C, Sage J. Small-cell lung cancer. Nat Rev Dis Primers. 2021;7:3.
2. Gazdar AF, Bunn PA, Minna JD. Small-cell lung cancer: what we know, what we need to know and the path forward. Nat Rev Cancer. 2017;17:725–737.
3. Sabari JK, Lok BH, Laird JH, Poirier JT, Rudin CM. Unravelling the biology of SCLC: implications for therapy. Nat Rev Clin Oncol. 2017;14:549–561.
4. Howlader N, Forjaz G, Mooradian MJ, et al. The effect of advances in lung-cancer treatment on population mortality. N Engl J Med. 2020;383:640–649.
5. Horn L, Mansfield AS, Szczesna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379:2220-2229.

6. Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394:1929-1939.

7. Liu SV, Reck M, Mansfield AS, et al. Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133). J Clin Oncol. 2021;39:619-630.

8. Goldman JW, Dvorkin M, Chen Y, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2021;22:51-65.

9. Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature. 2013;500:415-421.

10. Yarchoan M, Hopkins A, Jaffe EM. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med. 2017;377:2500-2501.

11. Rekhtman N, Pietanza MC, Hellmann MD, et al. Next-generation sequencing of pulmonary large cell neuroendocrine carcinoma reveals small cell carcinoma-like and non-small cell carcinoma-like subsets. Clin Cancer Res. 2016;22:3618-3629.

12. Chalmers ZR, Connelly CF, Fabrizio D, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9:34.

13. Carvajal-Hausdorf D, Altan M, Velcheti V, et al. Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung cancer (SCLC). J Immunother Cancer. 2019;7:65.

14. Bonanno L, Pavan A, Dieci MV, et al. The role of immune microenvironment in small-cell lung cancer: distribution of PD-L1 expression and prognostic role of FOXP3-positive tumour infiltrating lymphocytes. Eur J Cancer. 2018;101:191-200.

15. Yu H, Batenchuk C, Badzio A, et al. PD-L1 expression by two complementary diagnostic assays and mRNA in situ hybridization in small cell lung cancer. J Thorac Oncol. 2017;12:110-120.

16. Schultheis AM, Scheel AH, Ozretic L, et al. PD-L1 expression in small cell neuroendocrine carcinomas. Eur J Cancer. 2015;51:421-426.

17. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline version 1.1. Eur J Cancer. 2009;45:228-247.

18. Ayers M, Lunceford J, Nebozhyn M, et al. IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017;127:2930-2940.

19. Ott PA, Bang YJ, Piha-Paul SA, et al. T-cell-inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028. J Clin Oncol. 2019;37:318-327.

20. Zhang Q, Bi J, Zheng X, et al. Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity. Nat Immunol. 2018;19:723-732.

21. Turajlic S, Litchfield K, Xu H, et al. Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. Lancet Oncol. 2017;18:1009-1021.

22. Cristescu R, Mogg R, Ayers M, et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science. 2018;362:eaa3593.

23. Smith CC, Selitsky SR, Chai S, Armstead PM, Vincent BG, Serody JS. Alternative tumour-specific antigens. Nat Rev Cancer. 2019;19:465-478.

24. De Mattos-Arruda L, Vazquez M, Finotello F, et al. Neoantigen prediction and computational perspectives towards clinical benefit: recommendations from the ESMO Precision Medicine Working Group. Ann Oncol. 2020;31:978-990.

25. Ready NE, Ott PA, Hellmann MD, et al. Nivolumab monotherapy and nivolumab plus ipilimumab in recurrent small cell lung cancer: results from the CheckMate 032 randomized cohort. J Thorac Oncol. 2020;15:426-435.

26. Chung HC, Piha-Paul SA, Lopez-Martin J, et al. Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC: results from the KEYNOTE-028 and KEYNOTE-158 studies. J Thorac Oncol. 2020;15:618-627.

27. Teng MW, Ngiov SF, Ribas A, Smyth MJ. Classifying cancers based on T-cell infiltration and PD-L1. Cancer Res. 2015;75:2139-2145.

28. Taube JM, Anders RA, Young GD, et al. Colocalization of inflammatory response with B7-H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 2012;4:127ra137.

29. Remon J, Aldea M, Besse B, et al. Small cell lung cancer: a slightly less orphan disease after immunotherapy. Ann Oncol. 2021;32:698-709.

30. Byers LA, Wang J, Nilsson MB, et al. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov. 2012;2:798-811.

31. Doerr F, George J, Schmitt A, et al. Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer. Sci Rep. 2017;7:15511.

32. Sen T, Gay CM, Byers LA. Targeting DNA damage repair in small cell lung cancer and the biomarker landscape. Transl Lung Cancer Res. 2018;7:50-68.

33. Jatiani SS, Christie S, Leshchenko VV, et al. SOX11 inhibitors are cytotoxic in mantle cell lymphoma. Clin Cancer Res. 2021;27:4652-4663.

34. Zou M, Toivanen R, Mitrofanova A, et al. Transdifferentiation as a mechanism of treatment resistance in a mouse model of castration-resistant prostate cancer. Cancer Discov. 2017;7:736-749.

35. Cai L, Liu H, Huang F, et al. Cell-autonomous immune gene expression is repressed in pulmonary neuroendocrine cells and small cell lung cancer. Commun Biol. 2021;4:314.
36. Dora D, Rivard C, Yu H, et al. Neuroendocrine subtypes of small cell lung cancer differ in terms of immune microenvironment and checkpoint molecule distribution. *Mol Oncol*. 2020;14:1947-1965.

37. Casey SC, Tong L, Li Y, et al. MYC regulates the antitumor immune response through CD47 and PD-L1. *Science*. 2016;352:227-231.

38. Bragelmann J, Bohm S, Guthrie MR, Mollaoglu G, Oliver TG, Sos ML. Family matters: how MYC family oncoproteins impact small cell lung cancer. *Cell Cycle*. 2017;16:1489-1498.

39. Ireland AS, Micinski AM, Kastner DW, et al. MYC drives temporal evolution of small cell lung cancer subtypes by reprogramming neuroendocrine fate. *Cancer Cell*. 2020;38:60-78.e12.

40. Goldman JW, Garassino MC, Chen Y, et al. LBA86 durvalumab (D) ± tremelimumab (T) + platinum-etoposide (EP) in 1L ES-SCLC: characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN. *Ann Oncol*. 2020;31(suppl 4):S1212-S1213.

41. Rudin CM, Poirier JT, Byers LA, et al. Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. *Nat Rev Cancer*. 2019;19:289-297.

42. Gay CM, Stewart CA, Park EM, et al. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. *Cancer Cell*. 2021;39:346-360.e7.